Table 2. Comparison between second-line chemotherapy group and non-second-line chemotherapy group.

Characteristic	Yes			No		P value
	N	%		N	%
Age at met diagnosis						<0.001
N	65			33
Mean (SD)	61 (10.0)			68 (10.0)
Median [Min–Max]	61 [25–78]			67 [37–84]
Baseline BMI or height and weight at baseline						0.916
N	65			33
Mean (SD)	26.88 (4.57)			27.36 (5.84)
Median [Min–Max]	26.10 [18.10–39.10]			26.90 [20.40–46.10]
Follow-up (months)						<0.001
N	65			33
Mean (SD)	10.11 (6.29)			4.73 (3.33)
Median (Min–Max)	8.51 (3.16–38.05)			3.88 (1.88–19.29)
Age						0.418
<50	6	9.23		1	3.03
≥50	59	90.77		32	96.97
Gender						0.125
Male	42	64.62		16	48.48
Female	23	35.38		17	51.52
ECOG PS at diagnosis						0.021
0	10	18.87		3	10.34
1	39	73.58		17	58.62
2–3	4	7.55		9	31.03
Overweight/obese						0.588
No	22	33.85		13	39.39
Yes	43	66.15		20	60.61
White						0.837
No	48	73.85		25	75.76
Yes	17	26.15		8	24.24
Site of disease						0.437
Head	31	47.69		19	57.58
Body	19	29.23		10	30.30
Tail	15	23.08		4	12.12
Metastatic disease sites						0.524
Diffuse	35	53.85		20	60.61
Single organ	30	46.15		13	39.39
1st line therapy						0.002
FOLFIRINOX	29	44.62		5	15.15
GA	29	44.62		28	84.85
Gem/Cis	2	3.08		0	0.00
FOLFOX/5-FU alone	1	1.54		0	0.00
Gem alone or erlotinib combo	3	4.62		0	0.00
Trial	1	1.54		0	0.00
CA 19-9 at first line start						0.276
<35	8	14.29		1	3.23
<59× ULN	24	42.86		14	45.16
>59× ULN	24	42.86		16	51.61
CA 19-9 at first line progression						0.999
<35	6	9.84		2	6.90
<59× ULN	23	37.70		11	37.93
>59× ULN	32	52.46		16	55.17